New Jersey Piscataway (AP) - Enzon pharmaceutical Monday before the opening after the jump, the company said that its board of directors was considering selling all or part of the company.
In the Piscataway, NJ, Enzon said it hired Lazard company's financial advisers in the review of its assets.
Biotechnology company also plans to stop development the androgen receptor scheme, hope to be able to save money.
, Enzon said, the establishment of the board of directors of a special committee to oversee its options.
President alex danner, said the company board of directors decided to sell some of its assets or shareholders' best interests. He said, in addition to Enzon strong balance sheet and royalty income, the candidate drugs and technologies for various trade to provide the possibility.
Enzon pharmaceutical company's stock price rose and cents, or 8%, to $4.95, dish before trading.




Other News:
Enzon board mulls sale of all or part of company
Judge denies Apple's request to ban US sales of Samsung smartphone models in pat
AIG selling rest of stake in AIA Group
Japan, China stocks higher on stimulus hopes
Spain's Santander studying how to absorb Banesto
Gas shortage exposes Pakistan's energy crisis
A Solo Stroll Through Baghdad
United Tech sees sales rising with Goodrich buy